A sense of urgency: Evaluating the link between clinical trial development time and the accrual performance of cancer therapy evaluation program (NCI-CTEP) sponsored studies

Clinical Cancer Research

Volumn 16, Issue 22, 2010, Pages 5557-5563

  Cheng, Steven K ^a,b   Dietrich, Mary S ^c   Dilts, David M ^a,b  

^a Center for Management Research in Healthcare   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF NURSING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER THERAPY; CLINICAL RESEARCH; EVALUATION; FUNDING; NATIONAL HEALTH ORGANIZATION; PRIORITY JOURNAL;

CLINICAL TRIALS AS TOPIC; HUMANS; NATIONAL CANCER INSTITUTE (U.S.); NEOPLASMS; PROGRAM EVALUATION; TIME FACTORS; UNITED STATES;

EID: 78349287749     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0133     Document Type: Article

References (14)

1. SEER cancer statistics review. 2008.
2. Heron M, Hoyert D, Xu J, Scott C, Tejada-Vera B. Deaths: preliminary data for 2006. Natl Vital Stat Rep 2008;56:1-52.
3. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 2004;291:2720-6.
4. Petrelli NJ, Grubbs S, Price K. Clinical trial investigator status: you need to earn it. J Clin Oncol 2008;26:2440-1.
5. Go RS, Frisby KA, Lee JA, et al. Clinical trial accrual among new cancer patients at a community-based cancer center. Cancer 2006;106:426-33.
6. Lara P, Jr., Higdon R, Lim N, et al. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol 2001;19:1728.
7. Mills EJ, Seely D, Rachlis B, et al. Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors. Lancet Oncol 2006;7:141-8.
8. Dilts DM, Sandler AB, Cheng SK, et al. Steps and time to process clinical trials at the Cancer Therapy Evaluation Program. J Clin Oncol 2009;27:1761-6.
9. Dilts DM, Sandler A, Cheng S, et al. Development of clinical trials in a cooperative group setting: the Eastern Cooperative Oncology Group. Clin Cancer Res 2008;14:3427-33.
10. Dilts DM, Sandler AB, Baker M, et al. Processes to activate phase III clinical trials in a Cooperative Oncology Group: the Case of Cancer and Leukemia Group B. J Clin Oncol 2006;24:4553-7.
11. Wheelwright SC, Clark KB. Revolutionizing product development: quantum leaps in speed, efficiency, and quality. New York, Toronto: Free Press; Maxwell Macmillan Canada; Maxwell Macmillan International; 1992.
12. Ansher S, Scharf R. The Cancer Therapy Evaluation Program (CTEP) at the National Cancer Institute. Ann N Y Acad Sci 2006;949:333-40.
13. Zerhouni EA. Translational and clinical science - time for a new vision. N Engl J Med 2005;353:1621-3.
14. Dilts DM, Sandler AB. Invisible barriers to clinical trials: the impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials. J Clin Oncol 2006;24:4545-52.